Pre-eclampsia, eclampsia and HELLP syndrome from the anaesthesiologist’s perspective
Authors:
Nosková Pavlína 1,2; Klozová Radka 1,3; Bláha Jan 1,2; Seidlová Dagmar 1,4; Štourač Petr 1,5
Authors‘ workplace:
Expertní skupina porodnické anestezie a analgezie ČSARIM
1; Klinika anesteziologie, resuscitace a intenzivní medicíny, 1. lékařská fakulta Univerzity Karlovy v Prazea Všeobecná fakultní nemocnice v Praze
2; Klinika anesteziologie a resuscitace, 2. lékařská fakulta Univerzity Karlovy v Praze a Fakultní nemocnicev Motole
3; II. anesteziologicko-resuscitační oddělení Fakultní nemocnice Brno
4; Klinika anesteziologie, resuscitace a intenzivní medicíny, Lékařská fakulta Masarykovy univerzitya Fakultní nemocnice Brno
5
Published in:
Anest. intenziv. Med., 24, 2013, č. 5, s. 350-356
Category:
Expert group of obstetric anaesthesia and analgesia
Overview
The text is a part of a series of articles by Expert Group of Obstetric Anesthesia and Analgesia (ESPAA) on current problems in obstetric anaesthesia. This article presents the current view of the treatment and anaesthesia practice and the consequences of pre-eclampsia, eclampsia and HELLP syndrome.
Keywords:
caesarean delivery – anaesthesia – pre-eclampsia – severe preeclampsia – eclampsia – HELLP syndrome
Sources
1. Al-Safi, Z. et al. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. Obstet. Gynecol., 2011, 118 (5), p. 1102–1107.
2. Yancey, L. M. et al. Postpartum preeclampsia: emergency department presentation and management. J. Emerg. Med., 2011,40 (4), p. 380–384.
3. Helewa, M. E., et al. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ, 1997, 157 (6), p. 715–725.
4. Wallis, A. B. et al. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension. United States 1987–2004. Am. J. Hypertens., 2008, 21 (5), p. 521–526.
5. Hutcheon, J. A., Lisonkova, S., Joseph, K. S. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol., 2011, 25 (4), p. 391–403.
6. Sibai, B. M. et al. What we have learned about preeclampsia. Semin. Perinatol., 2003, 27 (3), p. 239–246.
7. Duley, L. The global impact of pre-eclampsia and eclampsia. Semin. Perinatol., 2009, 33 (3): p. 130–137.
8. Meekins, J. W. et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol, 1994. 101(8): p. 669-74.
9. Maynard, S. E., Karumanchi, S. A. Angiogenic factors and preeclampsia. Semin. Nephrol., 2011, 31 (1), p. 33–46.
10. Duckitt, K., Harrington, D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ, 2005, 330 (7491), p. 565.
11. Štourač, P. Eklampsie. In Pařízek A. Kritické stavy v porodnictví. Praha: Galén 2012, s. 79–81.
12. Sibai, B. M. Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension, 2008, 52, 5, p. 805–806.
13. Verlohren, S., Stepan, H., Dechend, R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin. Sci. (Lond)., 2012, 122, 2, p. 43–52.
14. Stepan, H. et al. Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience. Z Geburtshilfe Neonatol., 2010, 214, 6, p. 234–248.
15. Podymow, T., August, P. Postpartum course of gestational hypertension and preeclampsia. Hypertens. Pregnancy, 2010, 29, 3, p. 294–300.
16. Wallace, D. H. et al. Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia. Obstet. Gynecol., 1995, 86, 2, p. 193–199.
17. Bláha, J. et al. Současné postupy v porodnické anestezii I. – peroperační péče u císařského řezu. Anest. intenziv. Med., 2013, 24, 2, p. 91–101.
18. Yoo, K. Y. et al. A dose-response study of remifentanil for attenuation of the hypertensive response to laryngoscopy and tracheal intubation in severely preeclamptic women undergoing caesarean delivery under general anaesthesia. Int. J. Obstet. Anesth., 2013, 22, 1, p. 10–18.
19. Park, B. Y. et al. Dose-related attenuation of cardiovascular responses to tracheal intubation by intravenous remifentanil bolus in severe pre-eclamptic patients undergoing Caesarean delivery. Br. J. Anaesth., 2011, 106, 1, p. 82–87.
20. Yoo, K. Y. et al. Effects of remifentanil on cardiovascular and bispectral index responses to endotracheal intubation in severe pre-eclamptic patients undergoing Caesarean delivery under general anaesthesia. Br. J. Anaesth., 2009, 102, 6, p. 812–819.
21. Richa, F. et al. General anesthesia with remifentanil for Cesarean section in a patient with HELLP syndrome. Acta Anaesthesiol. Scand., 2005, 49, 3, p. 418–420.
22. Magee, L. A. et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J. Obstet. Gynaecol. Can., 2008, 30, 3 Suppl, p. S1–48.
23. Altman, D. et al. Do women with pre-eclampsia, and theirbabies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet, 2002, 359, 9321, p. 1877–1890.
24. Lucas, M. J., Leveno, K. J., Cunningham, F. G. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N. Engl. J. Med., 1995, 333, 4, p. 201–205.
25. Belfort, M. A. et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N. Engl. J. Med., 2003, 348, 4, p. 304–311.
26. Ehrenberg, H. M., Mercer, B. M. Abbreviated postpartum magnesium sulfate therapy for women with mild preeclampsia: a randomized controlled trial. Obstet. Gynecol., 2006, 108, 4, p. 833–838.
27. Nežádoucí účinky léčiv – paracetamol, přehled účinnnosti a bezpečnosti. Informační zpravodaj Státního ústavu pro kontrolu léčiv, 2012, 5, 10, s. 2–3.
28. Preeclampsia a management, květen 2013. Dostupné z www: http://www.uptodate.com/contents/preeclampsia-management-and-prognosis?source=search_result&search=preeclampsia+management&selectedTitle=1~150.
29. Sibai, B. M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet. Gynecol., 2004, 103, 5 Pt, 1, p. 981–991.
30. O’Brien, J. M. et al. Maternal benefit of corticosteroid therapy in patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: impact on the rate of regional anesthesia. Am. J. Obstet. Gynecol., 2002, 186, 3, p. 475–479.
31. Matchaba, P., Moodley, J. Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database Syst. Rev., 2004, 1, p. CD002076.
32. Martin, J. N., Jr. et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am. J. Obstet. Gynecol., 2003, 189, 3, p. 830–834.
33. Fonseca, J. E. et al. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am. J. Obstet. Gynecol., 2005, 193, 5, p. 1591–1598.
34. Katz, L. et al. Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am. J. Obstet. Gynecol., 2008, 198, 3, p. 283 e1–8.
35. Woudstra, D. M. et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst. Rev., 2010(9): p. CD008148.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2013 Issue 5
Most read in this issue
- Multiple organ dysfunction syndrome
-
Skórovací schémata hodnocení sedace a výskytu deliria
I. Přehled skórovacích systémů hloubky sedace na JIP - Ultrasound assessment during admission of trauma and shocked patiens (FAST)
- Pre-eclampsia, eclampsia and HELLP syndrome from the anaesthesiologist’s perspective